Effects of corticosteroid and neuraminidase inhibitors on survival in patients with respiratory distress induced by influenza virus

Journal of Microbiology, Immunology and Infection

Volumn 50, Issue 5, 2017, Pages 586-594

  Huang, Shiang Fen ^a,b   Fung, Chang Phone ^a   Perng, Diahn Warng ^a   Wang, Fu Der ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

corticosteroid; H1N1; influenza; oseltamivir; peramivir

Indexed keywords

CORTICOSTEROID; IMIPENEM; OSELTAMIVIR; PERAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; SIALIDASE;

ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALL CAUSE MORTALITY; ARTICLE; ARTIFICIAL VENTILATION; CHRONIC LUNG DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEALTH SURVEY; HUMAN; INFLUENZA; INFLUENZA A; INFLUENZA B; INFLUENZA B VIRUS; INFLUENZA VIRUS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; PROGNOSIS; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; TAIWAN; TREATMENT DURATION; VIRUS STRAIN; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; DRUG EFFECT; DRUG INTERACTION; INFLUENZA A VIRUS (H1N1); METABOLIC SYNDROME X; MIDDLE AGED; ORTHOMYXOVIRIDAE; PATHOGENICITY; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CYCLOPENTANES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; GUANIDINES; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; METABOLIC SYNDROME; MIDDLE AGED; NEURAMINIDASE; ORTHOMYXOVIRIDAE; OSELTAMIVIR; RESPIRATORY DISTRESS SYNDROME, ADULT; RETROSPECTIVE STUDIES; TAIWAN; TREATMENT OUTCOME;

EID: 84953279985     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2015.08.016     Document Type: Article

References (38)

1. Yoshino, Y., Seo, K., Koga, I., Kitazawa, T., Ota, Y., Clinical efficacy of peramivir in adult patients with seasonal influenza during the winter of 2012 in Japan. Clin Respir J 9 (2015), 228–232.
2. Ison, M.G., Hui, D.S., Clezy, K., O'Neil, B.J., Flynt, A., Collis, P.J., et al. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults. Antivir Ther 18 (2013), 651–661.
3. Abed, Y., Boivin, G., Yoshida, R., Kodama, M., Hernandez, J.E., Parenteral peramivir treatment for Oseltamivir-resistant 2009 pandemic influenza A H1N1 viruses. J Infect Dis 204 (2011), 1641–1642.
4. Birnkrant, D., Cox, E., The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 361 (2009), 2204–2207.
5. Yu, Y., Garg, S., Yu, P.A., Kim, H.J., Patel, A., Merlin, T., Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010. Clin Infect Dis 55 (2012), 8–15.
6. Sorbello, A., Jones, S.C., Carter, W., Struble, K., Boucher, R., Truffa, M., et al. Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus. Clin Infect Dis 55 (2012), 1–7.
7. Hernandez, J.E., Adiga, R., Armstrong, R., Bazan, J., Bonilla, H., Bradley, J., et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States. Clin Infect Dis 52 (2011), 695–706.
8. Rodrigo, C., Leonardi-Bee, J., Nguyen-Van-Tam, J.S., Lim, W.S., Effect of corticosteroid therapy on influenza-related mortality: a systematic review and meta-analysis. J Infect Dis 212 (2015), 183–194.
9. Cortoos, P.J., Gilissen, C., Mol, P.G., Van den Bossche, F., Simoens, S., Willems, L., et al. Empirical management of community-acquired pneumonia: impact of concurrent A/H1N1 influenza pandemic on guideline implementation. J Antimicrob Chemother 66 (2011), 2864–2871.
10. Spieth, P.M., Zhang, H., Pharmacological therapies for acute respiratory distress syndrome. Curr Opin Crit Care 20 (2014), 113–121.
11. Yang, J.R., Kuo, C.Y., Huang, H.Y., Wu, F.T., Huang, Y.L., Cheng, C.Y., et al. Newly emerging mutations in the matrix genes of the human influenza A(H1N1)pdm09 and A(H3N2) viruses reduce the detection sensitivity of real-time reverse transcription-PCR. J Clin Microbiol 52 (2014), 76–82.
12. Yang, J.R., Lo, J., Liu, J.L., Lin, C.H., Ho, Y.L., Chen, C.J., et al. Rapid SYBR green I and modified probe real-time reverse transcription-PCR assays identify influenza H1N1 viruses and distinguish between pandemic and seasonal strains. J Clin Microbiol 47 (2009), 3714–3716.
13. Ward, C.L., Dempsey, M.H., Ring, C.J., Kempson, R.E., Zhang, L., Gor, D., et al. Design and performance testing of quantitative real time PCR assays for influenza A and B viral load measurement. J Clin Virol 29 (2004), 179–188.
14. Swho, G., (eds.) Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus, 1999, World Health Organization, Geneva.
15. Bantia, S., Upshaw, R., Babu, Y.S., Characterization of the binding affinities of peramivir and oseltamivir carboxylate to the neuraminidase enzyme. Antiviral Res 91 (2011), 288–291.
16. Park, S., Kim, J.I., Lee, I., Lee, S., Hwang, M.W., Bae, J.Y., et al. Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice. PLoS One, 9, 2014, e101325.
17. Smee, D.F., Hurst, B.L., Wong, M.H., Tarbet, E.B., Babu, Y.S., Klumpp, K., et al. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res 88 (2010), 38–44.
18. Hikita, T., Hikita, H., Hikita, F., Hikita, N., Hikita, S., Clinical effectiveness of peramivir in comparison with other neuraminidase inhibitors in pediatric influenza patients. Int J Pediatr, 2012, 2012, 834181.
19. Lee, N., Leo, Y.S., Cao, B., Chan, P.K., Kyaw, W.M., Uyeki, T.M., et al. Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients. Eur Respir J 45 (2015), 1642–1652.
20. de Jong, M.D., Ison, M.G., Monto, A.S., Metev, H., Clark, C., O'Neil, B., et al. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. Clin Infect Dis 59 (2014), e172–e185.
21. Sato, M., Ito, M., Suzuki, S., Sakuma, H., Takeyama, A., Oda, S., et al. Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variants. Antimicrob Agents Chemother 59 (2015), 1643–1649.
22. Hata, A., Akashi-Ueda, R., Takamatsu, K., Matsumura, T., Safety and efficacy of peramivir for influenza treatment. Drug Des Devel Ther 8 (2014), 2017–2038.
23. Almansa, R., Bermejo-Martin, J.F., de Lejarazu Leonardo, R.O., Immunopathogenesis of 2009 pandemic influenza. Enferm Infecc Microbiol Clin 30:Suppl. 4 (2012), 18–24.
24. Hu, Y., Lu, S., Song, Z., Wang, W., Hao, P., Li, J., et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381 (2013), 2273–2279.
25. Koul, P.A., Khan, U.H., Asad, R., Yousuf, R., Broor, S., Lal, R.B., et al. Contribution of influenza to acute exacerbations of chronic obstructive pulmonary disease in Kashmir, India, 2010-2012. Influenza Other Respir Viruses 9 (2015), 40–42.
26. Wang, Y.C., Lin, J.M., Li, C.Y., Lee, L.T., Guo, Y.L., Sung, F.C., Prevalence and risks of chronic airway obstruction: a population cohort study in Taiwan. Chest 131 (2007), 705–710.
27. Zhou, Y., Cowling, B.J., Wu, P., Chan, W.M., Lee, S.Y., Lau, E.H., et al. Adiposity and influenza-associated respiratory mortality: a cohort study. Clin Infect Dis 60 (2015), e49–57.
28. Cruz-Lagunas, A., Jiménez-Alvarez, L., Ramírez, G., Mendoza-Milla, C., García-Sancho, M.C., Avila-Moreno, F., et al. Obesity and pro-inflammatory mediators are associated with acute kidney injury in patients with A/H1N1 influenza and acute respiratory distress syndrome. Exp Mol Pathol 97 (2014), 453–457.
29. Zhang, A.J., To, K.K., Li, C., Lau, C.C., Poon, V.K., Chan, C.C., et al. Leptin mediates the pathogenesis of severe 2009 pandemic influenza A(H1N1) infection associated with cytokine dysregulation in mice with diet-induced obesity. J Infect Dis 207 (2013), 1270–1280.
30. Costanzo, A.E., Taylor, K.R., Dutt, S., Han, P.P., Fujioka, K., Jameson, J.M., Obesity impairs γδ T cell homeostasis and antiviral function in humans. PLoS One, 10, 2015, e0120918.
31. Karlsson, E.A., Sheridan, P.A., Beck, M.A., Diet-induced obesity impairs the T cell memory response to influenza virus infection. J Immunol 184 (2010), 3127–3133.
32. Quante, T., Ng, Y.C., Ramsay, E.E., Henness, S., Allen, J.C., Parmentier, J., et al. Corticosteroids reduce IL-6 in ASM cells via up-regulation of MKP-1. Am J Respir Cell Mol Biol 39 (2008), 208–217.
33. Levine, S.J., Larivée, P., Logun, C., Angus, C.W., Shelhamer, J.H., Corticosteroids differentially regulate secretion of IL-6, IL-8, and G-CSF by a human bronchial epithelial cell line. Am J Physiol 265 (1993), L360–L368.
34. Cheng, V.C., Lau, Y.K., Lee, K.L., Yiu, K.H., Chan, K.H., et al. Fatal co-infection with swine origin influenza virus A/H1N1 and community-acquired methicillin-resistant Staphylococcus aureus. J Infect 59 (2009), 366–370.
35. Hayashi, Y., Vaska, V.L., Baba, H., Nimmo, G.R., Davis, L., Paterson, D.L., Influenza-associated bacterial pathogens in patients with 2009 influenza A (H1N1) infection: impact of community-associated methicillin-resistant Staphylococcus aureus in Queensland, Australia. Intern Med J 42 (2012), 755–760.
36. Chung, D.R., Huh, K., Novel pandemic influenza A (H1N1) and community-associated methicillin-resistant Staphylococcus aureus pneumonia. Expert Rev Anti Infect Ther 13 (2015), 197–207.
37. Rynda-Apple, A., Harmsen, A., Erickson, A.S., Larson, K., Morton, R.V., Richert, L.E., et al. Regulation of IFN-gamma by IL-13 dictates susceptibility to secondary postinfluenza MRSA pneumonia. Eur J Immunol 44 (2014), 3263–3272.
38. Nin, N., Soto, L., Hurtado, J., Lorente, J.A., Buroni, M., Arancibia, F., et al. Clinical characteristics and outcomes of patients with 2009 influenza A(H1N1) virus infection with respiratory failure requiring mechanical ventilation. J Crit Care 26 (2011), 186–192.